The developer of treatments for cancer and bone fractures is branching out into the weight-loss market, but faces strong competition there Key Takeaways: At present, Jiuyuan Gene relies heavily on a bone repair product, Guyoudao, for around half its revenue The company is developing a generic version of the weight-loss drug Semaglutide, which is undergoing